Our study highlights the potential of stromal FAP expression as a companion biomarker for immunotherapy and reveals that targeting FAP is a promising strategy for increasing T cell infiltration and overcoming resistance to PD-1 blockade therapy in NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.